Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination

Objectives4CMenB is a broadly protective vaccine against invasive meningococcal capsular group B disease (MenB IMD). Licensed worldwide based on immunogenicity and safety data, effectiveness impact data are now available. We comprehensively reviewed all available real-world evidence gathered from use of 4CMenB since licensure.ResultsData 7 countries provide across different healthcare settings age-groups, including national/regional immunization programs, observational studies outbreak control. At least 2 doses reduced MenB IMD by 50%-100% in 2-month to 20-year-olds depending length follow-up. Estimates fully vaccinated cohorts ranged 59%-100%. The profile administered was consistent with pre-licensure clinical trial data.ConclusionMenB an uncommon but life-threatening unpredictable epidemiology. substantial body demonstrating supports its prevention. results reinforce the importance direct protection highest risk groups; infants/young children adolescents. Direct via routine infant catch-up young adolescent vaccination could be preferred option for control.A Video Abstract linked this article Figshare: https://doi.org/10.6084/m9.figshare.14546790.